Biotechnology News and Research

RSS

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

ICON Q1 2014 net revenue increases 10% to $349.6 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2014.

30 Apr 2014

InDevR, Applied Microarrays partner to offer complete system solution for multiplexed assays

InDevR Inc., a Boulder-based biotechnology company, and Applied Microarrays, Inc., a Tempe-based contract microarray manufacturer have partnered to deliver a complete system solution for multiplexed assays. The platform includes custom protein and DNA arrays, reagents and protocols, a fluorescent scanner for slides or plates (Vidia) and a colorimetric scanner for lower throughput applications (ampliPHOX).

30 Apr 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

GW University establishes new online integrative medicine program

The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.

29 Apr 2014

Researchers detect correlation between loss of Y chromosome and risk of cancer mortality

...

29 Apr 2014

Anaphylaxis Campaign's special conference to explore issues in allergy care

This special conference for our 20th Anniversary year will focus on providing a full and comprehensive round up of past, present and emerging themes and trends in allergy, care and management. The conference is free to all our Healthcare Professional Members and we are expecting over 70 clinicians in the field of allergy to attend.

29 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

APCER Pharma's revenues grew by more than 40% in 2013

APCER Pharma, the truly global provider of strategic and outsourced services for clinical safety, pharmacovigilance, medical affairs, and regulatory operations, announced today that revenues grew by more than 40% in 2013 compared to the previous year.

28 Apr 2014

Genetically modified E. coli has ability to produce D-ribose

D-ribose is a commercially important sugar used as a sweetener, a nutritional supplement, and as a starting compound for synthesizing riboflavin and several antiviral drugs.

26 Apr 2014

GEN Publishing introduces semi-monthly digital publication focusing on OMICs technologies

GEN Publishing recently introduced Clinical OMICs a semi-monthly digital publication focusing on the application of OMICs technologies in clinical settings. These advanced techniques, such as next-gen sequencing, are beginning to transform medical care just as they revolutionized basic life science research over the past decade-and-a-half.

26 Apr 2014

MGH investigators develop next-generation genome editing system

A next-generation genome editing system developed by Massachusetts General Hospital investigators substantially decreases the risk of producing unwanted, off-target gene mutations. In a paper receiving online publication in Nature Biotechnology, the researchers report a new CRISPR-based RNA-guided nuclease technology that uses two guide RNAs, significantly reducing the chance of cutting through DNA strands at mismatched sites.

26 Apr 2014

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited, has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a term loan in the principal amount of up to $35 million.

25 Apr 2014

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

25 Apr 2014

Studies report new genetic disorder associated with degeneration of central/peripheral nervous systems

A newly identified genetic disorder associated with degeneration of the central and peripheral nervous systems in humans, along with the genetic cause, is reported in the April 24, 2014 issue of Cell.

25 Apr 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013.

23 Apr 2014

WLSA's Convergence Summit to focus on global adoption of technology-enabled health care

The Wireless-Life Sciences Alliance said today that its ninth annual Convergence Summit here next month will focus on achieving broader global adoption of technology-enabled health care at a time when the pace of innovation in connected health and personal health solutions is accelerating.

23 Apr 2014

Biotechnology News and Research

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Biotech to the rescue

ICON Q1 2014 net revenue increases 10% to $349.6 million

InDevR, Applied Microarrays partner to offer complete system solution for multiplexed assays

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Bristol-Myers Squibb completes acquisition of iPierian

GW University establishes new online integrative medicine program

Researchers detect correlation between loss of Y chromosome and risk of cancer mortality

Anaphylaxis Campaign's special conference to explore issues in allergy care

Forest Laboratories enters into definitive agreement to acquire Furiex

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

APCER Pharma's revenues grew by more than 40% in 2013

Genetically modified E. coli has ability to produce D-ribose

GEN Publishing introduces semi-monthly digital publication focusing on OMICs technologies

MGH investigators develop next-generation genome editing system

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Studies report new genetic disorder associated with degeneration of central/peripheral nervous systems

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

WLSA's Convergence Summit to focus on global adoption of technology-enabled health care

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News